Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ia study to assess the safety and pharmacology of PAS-393 in human volunteers

Next Previous
Trial Profile

Phase Ia study to assess the safety and pharmacology of PAS-393 in human volunteers

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PAS-393 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 18 Sep 2020 New trial record
  • 15 Sep 2020 According to a Pascal Biosciences media release, Pascal Biosciences and SoRSE technology have entered into a Collaborative Research Agreement to advance Pascals PAS-393 into clinical testing in human volunteers. Following characterization of safety and pharmacology in a Phase 1a clinical trial, Pascal and SoRSE may elect to continue clinical development as equal partners in a Phase 1b cancer trial in combination with a checkpoint inhibitor.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top